Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublocade Maintenance Dosing in High-risk Opioid Use Disorder
NCT04995029Phase 4Completed
- Sponsor
- Indivior
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Indivior. Started Oct 2021; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04995029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995029.